Publications in collaboration with researchers from Harvard Medical School (1)

2023

  1. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 9, pp. 1029-1041